Earnings ·
Prothena reports Q3 net loss of $16.5M on $0.6M revenue, cash position at $272.2M
PRTAProthena Corp Public Ltd Co
Prothena Corporation reported a third-quarter 2026 net loss of $16.5 million, or $0.32 per share, compared to a $36.5 million loss in the prior-year period. Total revenue was $0.6 million, down from $2.4 million, as the company incurred $8.4 million in research and development expenses and $10.6 million in general and administrative costs. For the first nine months of 2026, net loss narrowed to $2.4 million on revenue of $52.7 million, driven by a $50.0 million milestone payment from Novo Nordisk. The company ended the quarter with $272.2 million in cash and no debt, while repurchasing approximately 501,492 shares under its buyback program. Prothena is a late-stage clinical biotechnology company focused on developing therapeutics for neurodegenerative and amyloid diseases.